Increased concentrations of neopterin have been described in patients with tumors of different primary locations, but reports on neopterin in patients with carcinoma of the esophagus are still very limited. We have studied serum neopterin in 45 patients with histologically verified carcinoma of the esophagus. Serum neopterin was determined with radioimmunoassay. Neopterin concentrations above median (6.5 nmol/L) were associated with inferior prognosis in patients with early esophageal carcinoma. In multivariate analysis, tumor stage and serum neopterin were predictors of survival in patients without distant metastases. In conclusion, serum neopterin is an independent prognostic factor in patients with esophageal carcinoma.
Introduction
Esophageal carcinoma is one of the most common malignancies worldwide. There are marked geographical variations in the incidence, and this tumor is relatively less common in Western countries (1) . The predominant histologic type is squamous cell carcinoma, but the proportion of patients with adenocarcinoma is rising. The prognosis of esophageal carcinoma is poor and the mortality approaches 90% of the incidence rate (2) . Unfortunately, only a minority of esophageal cancer patients present with resectable tumors, and after curative therapy long-term survival is obtained in only about 20% of resected patients (3, 4) . Most patients with initially localized esophageal carcinoma eventually die of locoregional recurrence or distant metastases (5) . Both progression of the primary or locoregional recurrence and distant metastases could represent the ultimate cause of death in an individual patient.
Neopterin is produced from guanosine triphosphate (GTP) by activated macrophages in a reaction catalyzed by GTP cyclohydrolase I, an enzyme induced by interferon-γ (IFN-γ). IFN-γ is produced by T-lymphocytes and natural killer cells. Pro-inflammatory cytokines, e.g. interleukin-1 or interleukin-6, are known to enhance or, in some instances, induce neopterin production, and neopterin concentrations therefore reflect both systemic immune and inflammatory response (6) . The determination of both serum and urinary neopterin concentrations has been validated as a marker of systemic immune and inflammatory response in wide spectrum of disorders, including cancer, viral infections, transplant rejection, or acute myocardial infarction (6) (7) (8) . In patients with tumors of different primary locations, increased serum or urinary neopterin concentrations were associated with poor prognosis (8) (9) (10) .
The literature on neopterin as a marker of systemic immune activation in patients with esophageal carcinoma is limited. We have reported on a study in 45 patients with esophageal carcinoma noting that serum neopterin is increased in patients with this disease (11) . The prognostic significance of serum neopterin concentrations in this cohort was not examined at the time of initial report because of limited number of events. In this paper we report the results of survival analysis after a longer follow-up.
Material and Methods
Forty-five patients with histologically verified esophageal carcinoma were included in the present analysis. The present cohort has been described and reported earlier (11) . Serum neopterin was determined with radioimmunoassay (BRAHMS, Hennigsdorf, Germany) as described (11) . The majority of the patients were treated with a chemoradiation regimen comprising systemic administration of cisplatin and 5-fluorouracil, and external beam radiation therapy, followed by surgery or observation. Patients with distant metastases were treated with systemic chemotherapy (combination of 5-fluorouracil) or, in case of poor general condition, with best supportive care only. Best supportive care was also the only treatment possible in 2 patients without distant metastases in whom the poor general condition precluded the administration of anticancer therapy. The samples were obtained before any treatment in 42 patients, and after chemoradiation in 3 patients.
Overall survival was evaluated with the KaplanMeier method, and the differences between subgroups of patients defined by clinical parameters or dichotomization of neopterin concentrations were studied by log-rank test. Multivariate analysis was performed using Cox regression. All dichotomized clinical and pathological variables were entered into a hierarchical forward and switching model and the results were expressed as hazard ratio (HR). The decision on statistical significance was based on p = 0.05 level. The analyses were performed using NCSS software (Number Cruncher Statistical Systems, Kaysville, Utah, USA).
Results
At the time of the analysis, only 7 patients (16%) were alive. The median survival of all patients was 12.9 months, and median follow-up of surviving patients was 34 (range 31 -38) months. Twenty-eight patients had squamous cell carcinoma and 17 patients had adenocarcinoma. Twenty-three patients had stage I-IIa, 13 patients had stage IIb-III and 9 patients had stage IV (metastatic) esophageal carcinoma. Median of serum neopterin concentrations was 6.5 nmol/L. The values in individual patients were dichotomized based on this median (below vs. equal or above 6.5 nmol/L).
Median survival in stage I-IIa patients was 15.2 months, in stage IIb-III patients 9.6 months and in stage IV patients 9.9 months. Median survival times of patients with adenocarcinoma and squamous cell carcinoma were 9.2 months and 13.7 months, respectively. In the whole group of patients, no significant difference was observed between the survival of patients with serum neopterin concentrations <6.5 nmol/L vs. (Table 1) .
Further analysis of prognostic significance of serum neopterin concentrations, histology and stage was performed in patients with non-metastatic disease. None of these factors was significant in univariate analysis (Table 2) . In multivariate analysis, lower serum neopterin and lower stage were predictive of better survival (Table 3) .
Discussion
To the best of our knowledge, the present analysis is the first to suggest prognostic significance of neopterin concentrations in patients with esophageal carcinoma. In the univariate analysis, serum neopterin was of borderline statistical significance in patients with early esophageal carcinoma. It is interesting to note that while the survival of patients with early stage esophageal carcinoma during the first year was independent of neopterin concentrations, the survival curves diverged after 12 months, and, except for one patient, all survivors had low initial neopterin concentrations. Similar trend was evident in patients with more advanced non-metastatic esophageal carcinoma. It is possible that increased serum neopterin concentrations predict the presence of occult distant metastases that would progress and ultimately lead to the death of the patients. Patients with esophageal carcinoma are treated with aggressive therapy that includes combination of external beam radiation and systemic chemotherapy with surgery that is associated with significant morbidity and mortality, and identification of patients who will ultimately benefit from these treatments is of obvious importance. The present observa- 
12.9 vs. 13.5 0.09 > > tion suggesting that neopterin may identify long-term survivors in patients with early esophageal carcinoma should be confirmed in further prospective clinical trials. In patients with metastatic disease, an opposite trend of decreased survival of patients with low neopterin concentrations was observed, but this is based on only 3 cases. In general, the number of patients with advanced esophageal carcinoma was limited in the present study, and no conclusion about the significance of neopterin in this subgroup can be postulated. These data should be regarded as hypothesisgenerating and should be confirmed in prospective studies. On the other hand, survival data in the present cohort seem to be mature as the proportion of surviving patients (16%) corresponds to long-term survival of patients with esophageal carcinoma, and few additional events would be expected in the present cohort.
In the present analysis, the prognostic impact of higher neopterin in patients without distant metastases was in the multivariate analysis similar to the prognostic significance of stage. In previous investigations, it has been demonstrated that neopterin is a prognostic indicator in patients with different tumors, including gastrointestinal malignancies (8, 12, 13) . In Western countries, esophageal carcinoma is a less common tumor, and studies investigating neopterin in patients with this disease are still limited (11, 12) . Prognostic significance of urinary neopterin concentrations was also demonstrated in a cohort of patients with upper gastrointestinal malignancies that included only one patient with esophageal carcinoma (12) .
Increased neopterin concentrations were associated with poor survival also in cohorts of subjects other than cancer patients, e.g. in the elderly (14) . Correlations were observed between lower numbers or impaired function of lymphocytes or dendritic cells and neopterin concentrations (15) (16) (17) (18) . Thus, increased systemic neopterin concentrations are thought to reflect immune dysregulation (9) . In cancer patients, immune dysregulation that is revealed by increased neopterin concentrations is the result of stimulation of the host inflammatory response by the growing neoplasm and failure of the immune system to control tumor growth and progression.
In conclusion, serum neopterin is an independent prognostic indicator in patients with esophageal carcinoma. Further prospective studies should assess the utility of neopterin determination in therapeutic decisions in individuals affected by this lethal malignancy. 
